Legend Biotech Net Debt Growth & History (LEGN)
Legend Biotech's net debt was −$488.2M for fiscal 2025.
View full Legend Biotech company overviewLegend Biotech annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$488.2M | −$500.9M | — |
| 2024 | 2024-12-31 | $12.7M | $993.1M | — |
| 2023 | 2023-12-31 | −$980.4M | −$468.0M | — |
| 2022 | 2022-12-31 | −$512.4M | $54.3M | — |
| 2021 | 2021-12-31 | −$566.7M | −$114.4M | — |
| 2020 | 2020-12-31 | −$452.3M | −$375.0M | — |
| 2019 | 2019-12-31 | −$77.3M | — | — |
Legend Biotech quarterly net debt
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$394.7M | −$455.8M | — |
| Q1 2026 | 2026-03-31 | −$257.1M | −$122.5M | — |
| Q4 2025 | 2025-12-31 | −$488.2M | −$500.9M | — |
| Q3 2025 | 2025-09-30 | $131.3M | $290.7M | — |
| Q2 2025 | 2025-06-30 | $61.1M | −$35.1M | −36.47% |
| Q1 2025 | 2025-03-31 | −$134.6M | $464.6M | — |
| Q4 2024 | 2024-12-31 | $12.7M | $993.1M | — |
| Q3 2024 | 2024-09-30 | −$159.3M | $509.6M | — |
| Q2 2024 | 2024-06-30 | $96.1M | $1.03B | — |
| Q1 2024 | 2024-03-31 | −$599.3M | — | — |
| Q4 2023 | 2023-12-31 | −$980.4M | −$468.0M | — |
| Q3 2023 | 2023-09-30 | −$668.9M | — | — |
| Q2 2023 | 2023-06-30 | −$935.2M | — | — |
| Q4 2022 | 2022-12-31 | −$512.4M | $54.3M | — |
| Q4 2021 | 2021-12-31 | −$566.7M | −$114.4M | — |
| Q2 2021 | 2021-06-30 | −$468.1M | — | — |
| Q4 2020 | 2020-12-31 | −$452.3M | — | — |
Legend Biotech net debt trends
Over the last five fiscal years, Legend Biotech's net debt decreased from −$452.3M to −$488.2M, a change of −$35.9M. The latest reported quarter, Q2 2026, shows −$394.7M.
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Legend Biotech source filings ↗